RxDoctor Payments Data

Peter Benet, MD

Psychiatry · South Windsor, CTNPI 1134230394

Payments from drug & device makers

$1,597in general payments, 2019–2025

Across 116 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$659
  • Johnson & Johnson$353
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$236
  • Sunovion Pharmaceuticals Inc.$137
  • Corium, LLC$77
  • Alkermes, Inc.$58
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$1,55097%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,597 in reported general payments places this provider in the 80th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$123,500
Medicare patients
52
Services billed
1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl284$354,867
VraylarCariprazine Hcl79$132,986
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl202$57,699
ZubsolvBuprenorphine Hcl/Naloxone Hcl30$31,424
LybalviOlanzapine/Samidorphan Malate13$21,060
SuboxoneBuprenorphine Hcl/Naloxone Hcl30$20,942
Adderall XrDextroamphetamine/Amphetamine15$9,231
Clomipramine Hcl25$4,428
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine59$3,187
Clonazepam236$1,964
Methylphenidate Er (La)Methylphenidate Hcl12$1,907
Aripiprazole30$1,754
Bupropion XlBupropion Hcl58$1,521
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine57$1,287
Gabapentin71$1,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$353$354,867284 claims
AbbVieVraylar$659$132,98679 claims
Orexo US, Inc.Zubsolv$16$31,42430 claims
Alkermes, Inc.Lybalvi$58$21,06013 claims
Almatica Pharma LLCSertraline Hcl$26$28757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in South Windsor

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →